
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is expected to have a strong year ahead as it continues to execute on the ongoing Phase 2a GAlette study for OpRegen, which is evaluating subretinal delivery optimization and safety. The company has already achieved several milestones under its partnership with Roche and Genentech, including positive 36-month data for OpRegen in geographic atrophy secondary to Age-Related Macular Degeneration and a cash milestone payment. Additionally, Lineage is making progress in expanding its pipeline and manufacturing capabilities, with a focus on developing treatments for other degenerative diseases such as spinal cord injury and Type 1 diabetes.
Bears say
Lineage Cell Therapeutics is a clinical-stage biotech company that faces significant risks in its operations, including clinical/regulatory and financial risk, as well as potential legal and IP risks. Despite recent progress in its allogeneic cell transplant platform and potential partnerships, the company faces uncertain commercial success in its various programs, highlighted by a relatively modest 2023 revenue projection of just $24.9 million, which may pose challenges to its long-term sustainability and market share. Moreover, with a current market cap of $358.6 million, the company has a relatively high valuation for a clinical-stage biotech, potentially exposing investors to further downside risk if its pipeline development experiences setbacks or delays.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares